Millennium Magazine_3rdEd

168 Millennium - A Marquis Who’s Who Magazine journals. Prior to founding Cloaked Therapeutics, LLC, Dr. McChesney served the University of Kansas as a faculty member; the University of Mississippi as director of theResearch Instituteof Pharmaceutical Sciences, NaPro BioTherapeutics, Inc., as vice president; and Tapestry Pharmaceuticals and ChromaDex, Inc., as chief scientific officer. Until 2017, he was also the principal owner and founder of Ironstone Separations, Inc., as well as the managing director and founder of Arbor Therapeutics LLC since 2010. In recognition of his exceptional undertakings, Dr.McChesneywas nameda fellowof theAmerican Society of Pharmacognosy and the American Association for the Advancement of Science. He was also named an F.A.P. Barnard Professor at the University of Mississippi, and he received the Outstanding Teaching Award from the University of Kansas. He attributes his immense success to his diligent work ethic and good fortune. W ith much of his childhood spent immersed in nature on farmlands, Dr. James D. McChesney developed an interest in the natural world from an early age. Attending college as a young adult, he received a BS in chemical technology from Iowa State University, as well as an MA in botany and PhD in organic chemistry from Indiana University Bloomington. Having spent the earlier portion of his career in executive and educational roles, he has served Cloaked Therapeutics, LLC, as founder, chairman and chief executive officer since 2014. Lauded for his focus on natural products chemistry, Dr. McChesney founded his company as a means of improving cancer chemotherapy. Since the inception of his career, he has been applauded for multiple accomplishments, including the conception and implementation of the National Center for Natural Products Research at the University of Mississippi campus in Oxford; the design and development of a third-generation taxane anticancer agent (TPI 287), which is now in clinical development; and the design of a new 8-aminoquinoline anti-malarial agent that has reduced hemolytic toxicity (NPC 1161B), which is in advanced preclinical development. In addition to these achievements, he has obtained 45 patents and contributedmore than 200 articles to scientific JAMES D. MCCHESNEY, PHD CHAIRMAN, CHIEF EXECUTIVE OFFICER Cloaked Therapeutics, LLC Etta, MS SCIENCES, PHARMACEUTICALS AND BIOTECHNOLOGY